These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 7538251)

  • 21. Evolutionary study of hepatitis C virus envelope genes during primary infection.
    Chen S; Wang YM
    Chin Med J (Engl); 2007 Dec; 120(24):2174-80. PubMed ID: 18167197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-cell epitopes in hypervariable region 1 of hepatitis C virus obtained from patients with chronic persistent hepatitis.
    Nakamoto Y; Kaneko S; Ohno H; Honda M; Unoura M; Murakami S; Kobayashi K
    J Med Virol; 1996 Sep; 50(1):35-41. PubMed ID: 8890039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus.
    Zhou YH; Moriyama M; Esumi M
    Virology; 1999 Apr; 256(2):360-70. PubMed ID: 10191201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E2 quasispecies specificity of hepatitis C virus association with allografts immediately after liver transplantation.
    Hughes MG; Rudy CK; Chong TW; Smith RL; Evans HL; Iezzoni JC; Sawyer RG; Pruett TL
    Liver Transpl; 2004 Feb; 10(2):208-16. PubMed ID: 14762858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
    Shao S; Zhou H; Tong Y; Ren Y; Chen Z
    Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library.
    Mink MA; Benichou S; Madaule P; Tiollais P; Prince AM; Inchauspe G
    Virology; 1994 Apr; 200(1):246-55. PubMed ID: 7510436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.
    Penin F; Combet C; Germanidis G; Frainais PO; Deléage G; Pawlotsky JM
    J Virol; 2001 Jun; 75(12):5703-10. PubMed ID: 11356980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region.
    Shirai M; Arichi T; Chen M; Masaki T; Nishioka M; Ikeda K; Takahashi H; Enomoto N; Saito T; Major ME; Nakazawa T; Akatsuka T; Feinstone SM; Berzofsky JA
    J Immunol; 1999 Jan; 162(1):568-76. PubMed ID: 9886434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of hypervariable region 1-specific and -cross-reactive CD4(+) T cells in HCV-infected individuals responsive to IFN-alpha treatment.
    Del Porto P; Puntoriero G; Scottà C; Nicosia A; Piccolella E
    Virology; 2000 Apr; 269(2):313-24. PubMed ID: 10753710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection.
    Scottà C; Garbuglia AR; Ruggeri L; Spada E; Laurenti L; Perrone MP; Girelli G; Mele A; Capobianchi MR; Folgori A; Nicosia A; Del Porto P; Piccolella E;
    J Hepatol; 2008 Feb; 48(2):216-28. PubMed ID: 18180071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease.
    Brambilla S; Bellati G; Asti M; Lisa A; Candusso ME; D'Amico M; Grassi G; Giacca M; Franchini A; Bruno S; Ideo G; Mondelli MU; Silini EM
    Hepatology; 1998 Jun; 27(6):1678-86. PubMed ID: 9620342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iatrogenic transmission of hepatitis C virus (HCV) by an anesthesiologist: comparative molecular analysis of the HCV-E1 and HCV-E2 hypervariable regions.
    Shemer-Avni Y; Cohen M; Keren-Naus A; Sikuler E; Hanuka N; Yaari A; Hayam E; Bachmatov L; Zemel R; Tur-Kaspa R
    Clin Infect Dis; 2007 Aug; 45(4):e32-8. PubMed ID: 17638183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody responses to the hepatitis C virus E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects.
    Cerino A; Bissolati M; Cividini A; Nicosia A; Esumi M; Hayashi N; Mizuno K; Slobbe R; Oudshoorn P; Silini E; Asti M; Mondelli MU
    J Med Virol; 1997 Jan; 51(1):1-5. PubMed ID: 8986942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.
    Kato N; Sekiya H; Ootsuyama Y; Nakazawa T; Hijikata M; Ohkoshi S; Shimotohno K
    J Virol; 1993 Jul; 67(7):3923-30. PubMed ID: 7685404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.